Top

Published in:

01-08-2018 | Review

Atrioventricular valve disease: challenges and achievements in percutaneous treatment

Authors: Roman Pfister, Stephan Baldus

Published in: Clinical Research in Cardiology | Special Issue 2/2018

Abstract

Percutaneous treatment of atrioventricular (AV) valve disease has long been restricted to therapy of mitral stenosis, and was only lately expanded to mitral regurgitation. 15 years ago the MitraClip edge to edge repair was first applied to human pathology. In Europe, German centers were the first to widely adopt this technique in patients with mitral regurgitation and high or inappropriate risk for surgery. Given the exponential rise in implantation procedures, expertise of the operators and investigator initiated investigations substantially contributed to improvements in procedural processes and patient selection. Meanwhile, additional techniques to repair the mitral and tricuspid valve were introduced to German interventionalists, both reconstructive techniques as well as first experiences with transcatheter implantation of mitral valve bioprostheses. Of note, specialized Heart Valve referral Centers catalyzed the adoption of these techniques. This review summarizes the contributions of German Heart Centers to recent developments in percutaneous therapy of AV valve disease.

Nkomo VT, Gardin JM, Skelton TN et al (2006) Burden of valvular heart diseases: a population-based study. Lancet 368:1005–1011CrossRefPubMed

d’Arcy JL, Coffey S, Loudon MA et al (2016) Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. Eur Heart J 37:3515–3522CrossRefPubMedPubMedCentral

Mirabel M, Iung B, Baron G et al (2007) What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J 28:1358–1365CrossRefPubMed

Condado JA, Acquatella H, Rodriguez L et al (2006) Percutaneous edge-to-edge mitral valve repair: 2-year follow-up in the first human case. Catheter Cardiovasc Interv 67:323–325CrossRefPubMed

Feldman T, Kar S, Elmariah S et al (2015) Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol 66:2844–2854CrossRefPubMed

Feldman T, Foster E, Glower DD et al (2011) Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 364:1395–1406CrossRefPubMed

Schofer J, Siminiak T, Haude M et al (2009) Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation 120:326–333CrossRefPubMedPubMedCentral

Franzen O, Baldus S, Rudolph V et al (2010) Acute outcomes of MitraClip therapy for mitral regurgitation in high-surgical-risk patients: emphasis on adverse valve morphology and severe left ventricular dysfunction. Eur Heart J 31:1373–1381CrossRefPubMed

Rudolph V, Knap M, Franzen O et al (2011) Echocardiographic and clinical outcomes of MitraClip therapy in patients not amenable to surgery. J Am Coll Cardiol 58:2190–2195CrossRefPubMed

10.

Baldus S, Schillinger W, Franzen O et al (2012) MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 14:1050–1055CrossRefPubMed

11.

Boekstegers P, Hausleiter J, Baldus S et al (2014) Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system. Clin Res Cardiol 103:85–96CrossRefPubMed

12.

Wallenborn J, Stork S, Herrmann S et al (2016) Prevalence of severe mitral regurgitation eligible for edge-to-edge mitral valve repair (MitraClip). Clin Res Cardiol 105:699–709CrossRefPubMed

13.

Schillinger W, Athanasiou T, Weicken N et al (2011) Impact of the learning curve on outcomes after percutaneous mitral valve repair with MitraClip and lessons learned after the first 75 consecutive patients. Eur J Heart Fail 13:1331–1339CrossRefPubMed

14.

Eggebrecht H, Mehta RH, Lubos E et al (2018) MitraClip in high- versus low-volume centers: an analysis from the German TRAMI registry. JACC Cardiovasc Interv 11:320–322CrossRefPubMed

15.

Baldus S, Kuck KH, Rudolph V et al (2018) Interventionelle Therapie von AV-Klappenerkrankungen - Fokus Mitralklappeninsuffizienz. Kardiologe 2:128–144

16.

de Waha S, Seeburger J, Ender J et al (2016) Deep sedation versus general anesthesia in percutaneous edge-to-edge mitral valve reconstruction using the MitraClip system. Clin Res Cardiol 105:535–543CrossRefPubMed

17.

Hellhammer K, Afzal S, Tigges R et al (2018) High body mass index is a risk factor for difficult deep sedation in percutaneous mitral valve repair. PLoS One 13:e0190590CrossRefPubMedPubMedCentral

18.

de Waha S, Desch S, Eitel I, Thiele H (2017) Response to Prof. Dr. med. Gunther Wiesner, Prof. Dr. med. Peter Tassani-Prell, and Dr. Patrick Mayr: Deep sedation versus general anaesthesia in percutaneous edge-to-edge mitral valve reconstruction using the MitraClip system. Clin Res Cardiol 106:162–163CrossRefPubMed

19.

Ledwoch J, Matic P, Franke J et al (2016) Transcatheter mitral valve repair with the MitraClip((R)) can be performed without general anesthesia and without conscious sedation. Clin Res Cardiol 105:297–306CrossRefPubMed

20.

Altiok E, Becker M, Hamada S et al (2011) Optimized guidance of percutaneous edge-to edge repair of the mitral valve using real-time 3-D transesophageal echocardiography. Clin Res Cardiol 100:675–681CrossRefPubMed

21.

Paranskaya L, Kische S, Akin I et al (2013) Combined use of rapid pacing and adenosine facilitates catheter based correction of severe bileaflet prolapse with the MitraClip system. Can J Cardiol 29:255.e1–255.e3

22.

Lubos E, Schluter M, Vettorazzi E et al (2014) MitraClip therapy in surgical high-risk patients: identification of echocardiographic variables affecting acute procedural outcome. JACC Cardiovasc Interv 7:394–402CrossRefPubMed

23.

Neuss M, Schau T, Isotani A et al (2017) Elevated mitral valve pressure gradient after MitraClip implantation deteriorates long-term outcome in patients with severe mitral regurgitation and severe heart failure. JACC Cardiovasc Interv 10:931–939CrossRefPubMed

24.

Ruf TF, Heidrich FM, Sveric KM et al (2017) ELMSTREET (Esophageal Lesions during MitraClip uSing TRansEsophageal Echocardiography Trial). EuroIntervention 13:e1444–e1451CrossRefPubMed

25.

Blazek S, Lurz P, Mangner N et al (2015) Incidence, characteristics and functional implications of cerebral embolic lesions after the MitraClip procedure. EuroIntervention 10:1195–1203CrossRefPubMed

26.

Frerker C, Schluter M, Sanchez OD et al (2016) Cerebral protection during MitraClip implantation: initial experience at 2 centers. JACC Cardiovasc Interv 9:171–179CrossRefPubMed

27.

Korber MI, Scherner M, Kuhr K et al (2018) Acute kidney injury following percutaneous edge-to-edge vs. minimally invasive surgical mitral valve repair: incidence, predictors and prognostic value. EuroIntervention 13:1645–1651CrossRefPubMed

28.

Korber MI, Silwedel J, Friedrichs K et al (2018) Bleeding complications after percutaneous mitral valve repair with the MitraClip. Am J Cardiol 121:94–99CrossRefPubMed

29.

Iliadis C, Lee S, Kuhr K et al (2017) Functional status and quality of life after transcatheter mitral valve repair: a prospective cohort study and systematic review. Clin Res Cardiol 106:1005–1017CrossRefPubMed

30.

Schueler R, Ozturk C, Sinning JM et al (2017) Impact of baseline tricuspid regurgitation on long-term clinical outcomes and survival after interventional edge-to-edge repair for mitral regurgitation. Clin Res Cardiol 106:350–358CrossRefPubMed

31.

Schwencke C, Bijuklic K, Ouarrak T et al (2017) Impact of cardiac comorbidities on early and 1-year outcome after percutaneous mitral valve interventions: data from the German transcatheter mitral valve interventions (TRAMI) registry. Clin Res Cardiol 106:249–258CrossRefPubMed

32.

Zuern CS, Bauer A, Lubos E et al (2015) Influence of non-cardiac comorbidities on outcome after percutaneous mitral valve repair: results from the German transcatheter mitral valve interventions (TRAMI) registry. Clin Res Cardiol 104:1044–1053CrossRefPubMed

33.

Ledwoch J, Franke J, Lubos E et al (2018) Prognostic value of preprocedural 6-min walk test in patients undergoing transcatheter mitral valve repair—insights from the German transcatheter mitral valve interventions registry. Clin Res Cardiol 107:241–248CrossRefPubMed

34.

Wiebe J, Franke J, Lubos E et al (2014) Percutaneous mitral valve repair with the MitraClip system according to the predicted risk by the logistic EuroSCORE: preliminary results from the German transcatheter mitral valve interventions (TRAMI) registry. Catheter Cardiovasc Interv 84:591–598CrossRefPubMed

35.

Lesevic H, Karl M, Braun D et al (2017) Long-term outcomes after MitraClip implantation according to the presence or absence of EVEREST inclusion criteria. Am J Cardiol 119:1255–1261CrossRefPubMed

36.

Schafer U, Maisano F, Butter C et al (2016) Impact of preprocedural left ventricular ejection fraction on 1-year outcomes after MitraClip implantation (from the ACCESS-EU phase I, a prospective, multicenter, nonrandomized postapproval study of the MitraClip therapy in Europe). Am J Cardiol 118:873–880CrossRefPubMed

37.

Rudolph V, Huntgeburth M, von Bardeleben RS et al (2014) Clinical outcome of critically ill, not fully recompensated, patients undergoing MitraClip therapy. Eur J Heart Fail 16:1223–1229CrossRefPubMed

38.

Neuss M, Schau T, Schoepp M et al (2013) Patient selection criteria and midterm clinical outcome for MitraClip therapy in patients with severe mitral regurgitation and severe congestive heart failure. Eur J Heart Fail 15:786–795CrossRefPubMed

39.

Metze C, Matzik AS, Scherner M et al (2017) Impact of frailty on outcomes in patients undergoing percutaneous mitral valve repair. JACC Cardiovasc Interv 10:1920–1929CrossRefPubMed

40.

Maisano F, Taramasso M, Nickenig G et al (2016) Cardioband, a transcatheter surgical-like direct mitral valve annuloplasty system: early results of the feasibility trial. Eur Heart J 37:817–825CrossRefPubMed

41.

Nickenig G, Hammerstingl C, Schueler R et al (2016) Transcatheter mitral annuloplasty in chronic functional mitral regurgitation: 6-month results with the cardioband percutaneous mitral repair system. JACC Cardiovasc Interv 9:2039–2047CrossRefPubMed

42.

Nickenig G, Schueler R, Dager A et al (2016) Treatment of chronic functional mitral valve regurgitation with a percutaneous annuloplasty system. J Am Coll Cardiol 67:2927–2936CrossRefPubMed

43.

Hammerstingl C, Schueler R, Malasa M et al (2016) Transcatheter treatment of severe tricuspid regurgitation with the MitraClip system. Eur Heart J 37:849–853CrossRefPubMed

44.

Nickenig G, Kowalski M, Hausleiter J et al (2017) Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge MitraClip technique. Circulation 135:1802–1814CrossRefPubMed

45.

Orban M, Besler C, Braun D et al (2018) Six-month outcome after transcatheter edge-to-edge repair of severe tricuspid regurgitation in patients with heart failure. Eur J Heart Fail 20:1055–1062CrossRef

Title: Atrioventricular valve disease: challenges and achievements in percutaneous treatment
Authors: Roman Pfister
Stephan Baldus
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue Special Issue 2/2018
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-018-1303-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Atrioventricular valve disease: challenges and achievements in percutaneous treatment

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2018

Genetics of coronary artery disease in the light of genome-wide association studies

Transcatheter aortic valve implantation in Germany

Current developments in cardiac rhythm management devices

Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University

The German Cardiac Society welcomes ESC in Munich

Complex PCI procedures: challenges for the interventional cardiologist

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page